img

ESC 2019

Here you will find the highlights of the ESC 2019 Congres, held on August 31st to September 4th in Paris, France.

ESC 2019 | CLARIFY: Los síntomas predicen riesgo solamente en pacientes con infarto previo

ESC 2019 | CLARIFY: Symptoms Predict Risk Only in Patients with Prior MI
The 5-year follow up of patients with chronic stable angina (or as the guidelines currently call it “chronic coronary syndrome”) indicate the risk of cardiovascular death or non-fatal MI is ...

ESC 2019 | Pure: el índice de masa corporal no tiene buena correlación con los eventos cardiovasculares

ESC 2019 | Pure: Body Mass Index Shows Low Correlation with Cardiovascular Events
This population study has found all-cause mortality is lower the lower body mass index (BMI) is, but lower BMI is not necessarily better. In fact, the lowest mortality in this ...

ESC 2019 | SYNTAXES: Ten-Year Outcomes!
The SYNTAXES (SYNTAX Extended Survival) was presented at ESC 2019 with somewhat unexpected results in favor of PCI. This is why the SYNTAX continues to be one of the best studies interventional ...

ESC 2019 | Nuevas guías Europeas sobre “síndromes coronarios crónicos”

ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes”
In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This ...

ESC 2019 | Complete: La evidencia definitiva para infartos con múltiples vasos

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease
For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards ...

ESC 2019 | CONDI-2ERIC-PPCI: punto final para el pre-acondicionamiento isquémico en angioplastia primaria

ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty
Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, according to this study presented ...

ESC 2019 | ISAR-REACT 5 | Prasugrel o ticagrelor en el SAC, ¿Cuál es mejor?

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?
Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best ...

ESC 2019 | EVOPACS: Evolocumab para reducir el colesterol en síndromes coronarios agudos

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes
Eight weeks of treatment with evolocumab added to a regimen of high-intensity statins in patients with acute coronary syndrome reduced significantly LDL cholesterol levels and was safe, compared ...

ESC 2019 | HOPE 4: derribar barreras para tratar factores de riesgo en países en desarrollo

ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries
Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in a significant reduction of systolic blood pressure, LDL ...

ESC 2019 | AFIRE: monoterapia de rivaroxabán en fibrilación auricular y enfermedad coronaria estable

ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD
In patients with atrial fibrillation and stable coronary artery disease who have not had revascularization procedures in the last 12 months, monotherapy with rivaroxaban seems the best treatment ...

ESC 2019 | DAPA-HF: Dapagliflozina muestra beneficios en todos los subgrupos

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups
Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and ...

ESC 2019 | ISAR-REACT 5 | Prasugrel o ticagrelor en el SAC, ¿Cuál es mejor?

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?
Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best ...

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.
The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in patients with cardiac failure symptoms and preserved ejection ...

ESC 2019 | THEMIS: ticagrelor en diabéticos con enfermedad coronaria estable

ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective
This is a sub-study of the THEMIS presented during the ESC 2019 scientific sessions in Paris, and simultaneously published in Lancet. They were all diabetics with stable coronary ...

ESC 2019 | THEMIS: ticagrelor en diabéticos con enfermedad coronaria estable

ESC 2019 | THEMIS: Ticagrelor in Diabetics with Stable Coronary Artery Disease
The use of ticagrelor in patients with stable coronary artery disease significantly reduces the rate of major cardiovascular events when compared against aspirin, according to this study presented ...

ESC 2019 | POPULAR AGE: el viejo clopidogrel sigue teniendo su lugar

ESC 2019 | POPULAR AGE: Good Old Clopidogrel Still Valid
According to this study, presented during the ESC 2019 scientific sessions, non-ST acute coronary syndrome (NSTE-ACS) patients treated with ticagrelor presented a significantly higher risk of ...

ESC 2019 | ¿Qué tan benigna es la estenosis aórtica moderada?

ESC 2019 | How Benign Is Moderate Aortic Stenosis?
Data from a great Australian registry of nearly 250,000 people with a 5-year follow-up, presented at the European Society of Cardiology (ESC) Congress 2019 in Paris and simultaneously published in ...

ESC 2019 | MITRA-FR: los resultados a 2 años de uno de los grandes estudios del MitraClip

ESC 2019 | MITRA-FR: 2-Year Outcomes of One of the Largest Studies on MitraClip
Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published only a few weeks later. According to the COAPT study, the MitraClip was ...

Top